Clinical Trial

Artificial Intelligence-Driven Medipixel Fractional Flow Reserve Versus Invasive Fractional Flow Reserve-Guided PCI Trial (AIM-FFR Trial)

Study acronym: AIM-FFR
Recruiting
View on ClinicalTrials.gov →
Summary
The AIM-FFR trial is a prospective, multi-center, open-label, randomized controlled, non-inferiority trial. The current trial will evaluate non-inferiority of MPFFR-guided PCI, compared with invasive FFR-guided PCI in patients with coronary artery disease.
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-24
Trial Details
NCT Number NCT07329699
Lead Sponsor Samsung Medical Center
Collaborators: Chonnam National University Hospital, Seoul National University Bundang Hospital, Chung-Ang University Gwangmyeong Hospital, The Catholic University of Korea, Keimyung University Dongsan Medical Center, Wonju Severance Christian Hospital, SMG-SNU Boramae Medical Center, Kangbuk Samsung Hospital, Sungkyunkwan University, Korea University Guro Hospital, Inje University Ilsan Paik Hospital, International St. Mary's Hospital, Kyungpook National University Hospital, Korea University Anam Hospital, Ajou University School of Medicine, Changwon Patima Hospital, Bundang CHA Hospital, Ulsan University Hospital, Gachon University Gil Medical Center, Inje University Haeundae Paik Hospital, Gyeongsang National University Changwon Hospital, Wonkwang University Hospital
Conditions Coronary Artery Disease, Chronic Coronary Syndrome, Acute Coronary Syndrome
Enrollment 2,100 participants
Start Date 2026-03-18
Primary Completion 2028-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-23